SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Scottish Enterprise Awards

9 Feb 2015 07:00

RNS Number : 3432E
Frontier IP Group plc
09 February 2015
 



 

 

AIM: FIPP

 

 

Frontier IP Group Plc

("Frontier IP")

 

Two portfolio companies win awards at Scottish Enterprise Life Sciences Awards 2015

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that two of its portfolio companies, ex scientia Ltd ("ex scientia"), and Aridhia Informatics Limited ("Aridhia"), each won an award at the prestigious Scottish Enterprise Life Sciences Awards.

 

Professor Andrew Hopkins, the founder and CEO of ex scientia secured the Life Sciences Entrepreneurial Business Leadership Award. ex scientia, a spin-out from the University of Dundee, is pioneering medicines tailored to polypharmacology for a wide range of human diseases. The award acknowledged Professor Hopkins's success as founder and chief executive of ex scientia, as well as his wider academic, commercial and fundraising activities.

 

Aridhia was a joint-winner of the Innovative Collaboration award alongside the University of Glasgow, NHS Greater Glasgow & Clyde, and Thermo Fisher Scientific Ltd, with the award recognising their collective contribution towards the modernisation of Glasgow's hospitals.

 

These awards, run by Scottish Enterprise, Scotland's main economic development agency, recognise the success and achievements of Scotland's internationally-renowned life sciences sector.

 

Neil Crabb, Chief Executive of Frontier IP, said:

 

"We are delighted to see the success of our portfolio companies being recognised and to congratulate Professor Andrew Hopkins of ex scientia and Aridhia on their prestigious awards."

 

 

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

Notes to Editor:

 

Frontier IP Group plc

www.frontierip.co.uk.

Frontier IP specialises in assisting universities, research institutions and companies in the commercialisation and exploitation of their Intellectual Property.

 

Scottish Enterprise

www.facebook.com/scottishenterprise

Scottish Enterprise is Scotland's main economic development agency and aims to deliver a significant, lasting effect for the Scottish economy. Their role is to help identify and exploit the best opportunities for economic growth. They support ambitious Scottish companies to compete within the global marketplace and help build Scotland's globally competitive sectors. They also work with a range of partners in the public and private sectors to attract new investment to Scotland and to help create a world-class business environment.

 

Ex Scientia Limited

www.exscientia.co.uk

Ex Scientia is a spinout company from the University of Dundee. Ex Scientia has been formed to exploit novel informatics and experimental methods to enable new, more effective, ways of conducting drug discovery.

 

Aridhia Informatics Limited

www.aridhia.com

Aridhia is a spinout and joint venture between University of Dundee, NHS Tayside and Sumerian Europe Ltd.

Aridhia applies innovative analytical and data integration techniques to deliver integrated information to improve healthcare. Aridhia provides actionable insight and joined-up information visibility to support improved healthcare outcomes from both an operational management and a clinical perspective.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASSDFWMFISEEE
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.